Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-12-19

Clinical Trial Update: Gemtuzumab in Treating Patients With Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

This update reports on a Phase 2 clinical trial evaluating gemtuzumab ozogamicin for myelodysplastic syndromes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Mylotarg (gemtuzumab ozogamicin)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: UNKNOWN